Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Francesco Menzella 1
Carla Galeone 1
Francesca Bertolini 2
Claudia Castagnetti 1
Nicola Facciolongo 1

1Department of Medical Specialties, Pneumology Unit, IRCCS- Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; 2Department of Animal Science, Iowa State University, Ames, IA, USA

Abstract: The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Other promising drugs will be available in the coming years, such as reslizumab, benralizumab, dupilumab and lebrikizumab. Moreover, since 2010, bronchial thermoplasty has been successfully introduced for a limited number of patients. This is a nonpharmacologic endoscopic procedure which is considered a promising therapy, even though several aspects still need to be clarified. Despite the increasing availability of new therapies, one of the major problems of each treatment is still the identification of the most suitable patients. This sudden abundance of therapeutic options, sometimes partially overlapping with each other, increases the importance to identify new biomarkers useful to guide the clinician in selecting the most appropriate patients and treatments, without forgetting the drug-economic aspects seen in elevated direct cost of new therapies. The aim of this review is, therefore, to update the clinician on the state of the art of therapies available for refractory asthma and, above all, to give useful directions that will help understand the different choices that sometimes partially overlap and to dispel the possible doubts that still exist.

Keywords: severe asthma, phenotypes, monoclonal antibodies, IL-5, bronchial thermoplasty, biomarkers

Introduction

In the last few years, there has been an increased understanding of the etiopathogenetic mechanisms and phenotypes of asthma, particularly in the field of molecular biology and immunogenetics. Through this knowledge, it has been possible to develop new therapeutic approaches for the treatment of several asthmatic phenotypes. This is increasing the potential to meet the unmet needs of patients with unsatisfactory control of asthma. These patients suffer from the side effects of systemic steroids, and this may have a high impact on the economic resources because of frequent access to health services.

For over a decade, the only available biologic therapy has been omalizumab, a monoclonal antibody (mAb) which is targeted to anti-IgE and is used for a specific subpopulation of patients with uncontrolled IgE-mediated allergic asthma. For these patients, omalizumab has been very effective and has made it possible to change the clinical history of patients that would have otherwise been condemned to a limited...
and burdensome life due to their respiratory conditions.\(^1\) For a long time, patients not eligible or not responsive to this treatment had to wait for the development of different therapies. Recently, new drugs and nonpharmacologic options are becoming available, showing encouraging results:

1. Biologic therapies with different mechanisms of action and targets. One of these molecules, the anti-interleukin 5 (anti-IL-5) mAb mepolizumab, has been recently approved for marketing. Other mAbs and new anti-inflammatory agents, such as prostaglandin receptor antagonists, will be available in the coming years.\(^2\)

2. Nonpharmacologic therapies, such as the bronchial thermoplasty (BT): This is still a controversial therapy because the efficacy is not always convincing and several aspects need to be clarified. This therapy may be applied on a large scale only after a clarification of all the concerns and doubts. As an invasive instrumental method, it may remain limited to centers with adequate experience and expertise. However, BT is showing extremely interesting results in terms of improving the quality of life (QoL) and reducing asthma exacerbation.\(^3\)

The availability of these new therapies enables addressing the patients to the most appropriate treatment and reducing therapeutic dropouts (Figure 1). These important actions can be facilitated by the identification of new biomarkers.

In this review, we will describe the therapies previously mentioned focusing on the treatments that are already available or that are on the most advanced stage of development. We will discuss the overlapping aspects of some of these treatments and their application in clinical practice. In this regard, the future availability of new molecules that are specific for different targets is gaining attention, considering that these targets are sometimes present in the same phenotype. This will make it difficult for the clinical task to choose the most suitable and the most effective drug. Understanding the role of the various therapeutic options, their differences and similarities and the doubts that still exist will simplify the clinical decision-making process and will allow obtaining the best result for the patient.

![Figure 1: Molecular targets of biologic drugs: action of the pathogenetic pathway of asthma at different levels.](https://www.dovepress.com/)

**Abbreviations:** IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; APC, antigen presenting cell.
From asthma phenotyping to personalized medicine

It is known that patients with asthma exhibit different levels of severity of their pathology, as well as several phenotypes and endotypes. This subdivision is primarily based on several clinical and immunological characteristics: allergic and nonallergic or “T2-high” and “T2-low”. The main inflammatory phenotypes can be eosinophilic or noneosinophilic, where the latter is subdivided into neutrophil or pauci-granulocytic.

The identification and definition of the endotypes has started only recently. This approach can be described as a single and distinct functional and physiopathologic mechanism that would enable a better use of existing drugs by identifying patient subgroups in order to find the more suitable treatment. Each endotype includes several asthmatic phenotypes that can be considered as “phenotypic clusters”. However, further studies need to be performed for a complete definition.

The phenotype-based therapy will strongly benefit from the future discoveries of genomics, proteomics and transcriptomics which are the subdisciplines of systems biology that will contribute to making the customization of therapies a real possibility.

IgE-mediated asthma and anti-IgE mAbs

In IgE-mediated asthma, the exposure to allergens results in an increased inflammation and worsening of respiratory function parameters. The cardinal role of this process is carried out by the IgE antibodies that bind to high-affinity (FcεRI) and low-affinity (FcεRII or CD23) receptors on the surface of mast cells and basophils and lead to subsequent degranulation and release of mediators.

Omalizumab (Xolair®) is a murine mAb (MAE11) that has been applied in clinical practice since 2005 for the treatment of severe allergic refractory asthma in patients sensitized to perennial allergens with serum IgE levels in the range of 30–1500 IU/mL (Figure 2; Table 1). This biologic is constructed by a somatic cell hybridization method, whose

![Figure 2](https://www.dovepress.com/)

**Figure 2** Flowchart for the selection of different treatment options.

**Abbreviation:** OCS, oral corticosteroids.
main feature is to present a paratope capable of binding to FcεRI and FcεRII receptors of basophils, dendritic cells and mast cells.11

To evaluate the effectiveness of omalizumab in patients with severe allergic uncontrolled asthma, several randomized clinical trials (RCTs) have been recently conducted. These studies demonstrated its efficacy and safety, with a significant reduction in the frequency of asthma exacerbations (up to 50%) and improvement in the QoL,12 as well as reduction in the use of oral corticosteroids (OCSs).12 The measurement of total IgE levels and body weight makes it possible to define its dosage, making this treatment the first to define a biologic treatment for asthma based on the use of a biomarker.13 This treatment showed good efficacy even in patients with nonallergic asthma, most often treated for longer periods,14 giving credit to the hypothesis that there is a local IgE production even without systemic sensitization.15 Other studies have confirmed its effectiveness in inner city children with resistant asthma,16 as well as in the prevention of seasonal exacerbations, thanks to a better interferon-α response to rhinoviruses.17 Recently, omalizumab has also been approved for the treatment of spontaneous chronic urticaria,18 while the increasing number of positive results on nasal polyposis provides new insights into this pathology that is often associated with asthma,19 regardless of the atopic status.

Based on the current data, omalizumab is indicated for continuing the treatment for an indefinite period, as the IgE levels and the number of FcεRI receptors tend to increase 3–4 weeks after its suspension. In this regard, several studies have confirmed that discontinuation of this treatment results in a worsening of asthma control, especially in patients with higher levels of eosinophilia, periostin and FeNO. These molecules seem to better respond to omalizumab drug, but they are the first to decay after suspension of the treatment.20,21 Recent studies also show an increase in clinical efficacy in the long term (up to 9 years of follow-up),22 with a favorable cost-effectiveness profile.23

Considering the intrinsic limitations of omalizumab, the subsequent evolution could be the application of mAbs with greater avidity for IgE, such as quilizumab (RG7449). This is a newly humanized mAb that binds to the M1 segment of the membrane IgE and targets the B lymphocytes before they are activated to produce IgE. The Controlled on Inhaled Steroids and a Second Controller trial is a 36-week, Phase II, randomized, placebo-controlled, double-blind study whose results have been recently published.24 These results show that quilizumab has a good safety profile and is associated with specific decrease in IgE serum levels up to 40%, without significant impact on exacerbations, respiratory functions and symptoms.25

Two other RCTs were designed to determine the safety, pharmacokinetics and efficacy ofquilizumab in patients with allergic rhinitis.26 In both studies, the treatment was tolerated and showed a significant reduction in persistent specific serum IgE up to 6 months after withdrawal, also blocking the production of new IgE after allergen challenge and reducing the eosinophils in induced sputum by over 50% compared to placebo.28

Another anti-IgE mAb is QGE031 (ligelizumab), a novel anti-IgE agent whose first studies showed a greater suppression of free IgE than omalizumab, including those with higher IgE levels.29

Despite the promising initial data, the Phase II study CQGE031B2201 failed to meet the primary objective of dem-
onstrating superiority of QGE031 versus placebo (Novartis Pharmaceuticals, unpublished data). Consequently, two other related Phase II trials were suspended following the failure of the core study.

Even if the premises were not positive, in a recent double-blind, parallel-group, multicenter study, 37 patients with mild allergic asthma were randomized to subcutaneous (SC) omalizumab, placebo or QGE031 at 24, 72 or 240 mg every 2 weeks for 10 weeks. Inhaled allergen challenge and skin tests were performed before dosing at 6, 12 and 18 weeks, and blood samples were collected until 24 weeks after the first dose. Ligelizumab appears to be more effective than omalizumab in terms of skin and inhalation response, demonstrating that it may be the most effective successor to omalizumab.

**Eosinophils and IL-5**

The eosinophilic granulocyte maturation, their recruitment and survival in the respiratory tract are determined by IL-3 and granulocyte–macrophage colony-stimulating factor, but above all by IL-5, which is the most important IL for the determination of eosinophilic airway inflammation. IL-5 induces the final differentiation of B cells activated into antibody-forming cells and enhances the proliferation and differentiation of the eosinophil precursors into mature eosinophils.

Eosinophils play a key role in several chronic respiratory conditions such as asthma, atopic diseases, viral infections, hypersensitivity to drugs and neoplastic conditions. For these reasons, several anti-IL-5 mAbs such as mepolizumab (Nucala®), reslizumab (Cinqair®) and benralizumab have been studied.

Mepolizumab is a humanized IgG1 nonglycosylated IgG1 antibody that binds to IL-5 and prevents the binding of IL-5 to its receptor. Early studies involved the application of mepolizumab for the treatment of idiopathic hypereosinophilic syndrome and Churg–Strauss syndrome or eosinophilic granulomatosis and polyangiitis, where a significant reduction in the use of OCS and a better control of the disease was observed. Other studies demonstrated that this molecule was ineffective in terms of improvement of respiratory function parameters (bronchial hyperresponsiveness, FEV1, PEF) and better asthma control (decreased rate of exacerbation) despite a decline in eosinophils in the blood and sputum. Based on later observations, described below, it was clear that there was a selection bias, concerning the blood eosinophilia and the severity of asthma criteria. The patients were not selected on the basis of blood eosinophils.

Two subsequent RCTs clearly showed how initially intravenous and SC mepolizumab could reduce the need for steroids and the number of exacerbations in patients with severe asthma with eosinophils >300 cells/μL, with less visible but positive effects on respiratory function parameters. A third registrative RCT confirmed the efficacy of mepolizumab in terms of reducing exacerbations, improving the QoL calculated by the Asthma Control Questionnaire 5 questionnaire and, above all, having an average reduction of 50% in the dose of OCS. A recent MUSCA trial (mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma) has confirmed that this drug significantly improved the health-related QoL in patients with severe eosinophilic asthma and had a security profile similar to placebo. In 2015, mepolizumab was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of severe eosinophilic asthma at a dose of 100 mg SC every 4 weeks (Figure 2; Table 1).

A second mAb anti-IL-5 is reslizumab. This drug has been studied in patients with uncontrolled eosinophilic asthma with a blood eosinophil level >400 cells/μL, showing a meaningful reduction of sputum eosinophil count, an improvement in QoL, FEV1 and control of the disease in terms of reducing exacerbations. The administration of reslizumab showed improved symptoms and QoL, even in case of nasal polyposis. The limitation of this drug may be the intravenous administration, since it is FDA approved only with this indication.

Benralizumab (MEDI-563) is an IgA1 mAb that binds the epitope on the α-subunit of the IL-5 receptor. It has been shown to reduce blood eosinophils and their precursors through the induction of antibody-mediated cell cytotoxicity (ADCC). Therefore, its molecular mechanism is completely different from that of mepolizumab. The benralizumab constant region (Fc) is afucosylated, leading to greater affinity for the Fc-gamma III receptor (FcγRIIIa) on the surface of the mast cells, basophils and natural killer cells, through which it induces ADCC on eosinophils and basophils. This involves a nearly complete depletion of eosinophils in sputum and tissues (90% and 96%, respectively) and a total disappearance...
in the bone marrow and blood. \(^5\) In Phase I and II RCTs on patients with severe eosinophilic asthma and peripheral eosinophils >300 cells/μL, SC benralizumab showed promising results, especially in terms of reducing EDN and ECP inflammation and inflammatory mediators as well as causing a significant reduction in blood eosinophils. \(^49,50\)

The main difference between benralizumab and other IL-5 mAb drugs is that benralizumab is independent of the circulating level of IL-5, which tends to increase during asthma exacerbations. The almost total depletion of eosinophils through ADCC prevents the effects caused by the activation by other related cytokines (IL-3 and granulocyte–macrophage colony-stimulating factor) that share the same receptor through the β subunit. The absence of fucose sugar residue in the molecular structure of benralizumab results in a much higher affinity for the FcγRIIIa receptor, overcoming the inhibitory effects of serum blocking IgGs. \(^47\) These features resulted in excellent efficacy data in terms of reduction of exacerbation rate and improvement in FEV1, \(^51,52\) significant reduction in blood eosinophils. \(^49,50\) in inflammation and inflammatory mediators as well as causing a significant reduction in the biomarkers associated with Th2-driven inflammation (TARC levels, eositin-3, FeNO). \(^59\)

Lebrikizumab (MILR1444A) is another humanized mAb having a specific target of IL-13. Lebrikizumab administered SC at doses of 125, 250 and 500 mg every 4 weeks showed an improved pulmonary function in extensive Phase II studies in patients with severe refractory asthma, with improved symptom control and reduced exacerbation, especially in the group with allergic phenotype with high levels of periostin and exogenous nitric oxide (FeNO). \(^59\) The improvement in FEV1 was also more apparent in the group with higher levels of periostin and FeNO, confirming the hypothesis that IL-13-driven phenomena are clinically important in these patients. \(^61,62\) Subsequently, two identical 52-week, Phase III studies had been conducted to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and II). LAVOLTA I met its primary endpoint, showing a significant reduction in the rate of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils. This study also showed a significant improvement in lung function. Unfortunately, these positive findings were not confirmed in LAVOLTA II, which did not show a significant reduction in asthma exacerbations. \(^63\)

**Block of IL-4/IL-13**

IL-4 and IL-13 are pleiotropic T-helper type 2 cytokines with a common pathway frequently associated with asthma and other atopic diseases such as atopic dermatitis. \(^55\) The main functions of IL-4 and IL-13 are the activation of the IgE isotype switch by plasma cells, the proliferation of some adhesion molecules on endothelial cells (especially VCAM-1) and stimulation of smooth bronchial muscle contractility. High levels of IL-13 are found in sputum and bronchial biopsies of patients with severe asthma, often not responsive to the use of systemic and inhaled steroids. This confirms the role of this cytokine in corticosteroid resistance. \(^56\) Some interesting mAbs in development aim to target these fundamental cytokines such as dupilumab, lebrikizumab and tralokinumab.

The mAb dupilumab inhibits the biologic effect of both IL-4 and IL-13 by preventing their interaction with IL-4 receptor α subunit. Recent studies have shown that this drug results in a significant decrease in exacerbations and better control of symptoms and pulmonary function, with concomitant reduction of inflammatory biomarkers related to the activity of Th2 lymphocytes, but with effects independent of eosinophils in serum in patients with severe refractory asthma. \(^57\) Recent trials on dupilumab administered SC as an add-on therapy at dose ranging from 100 to 300 mg showed an increase in pulmonary function and a significant reduction in severe exacerbations in patients with persistent asthma, without any difference in counting (±300 cells/μL) but with a favorable safety profile. \(^58,59\) Dupilumab also confirmed a marked reduction in the biomarkers associated with Th2-driven inflammation (TARC levels, eotaxin-3, FeNO). \(^59\)

**Antagonist of the prostaglandin D2 receptor**

Prostaglandin D2 (PGD2) is a prostanoid produced mostly by the mast cells in allergic diseases. The PGD2-induced vasodilatation and the subsequent increase in permeability are involved in inflammatory allergies. \(^66\) Prostanoid (DP)
receptors and the homologous receptor mutant molecule expressed on Th2 (CRTH2) cells have been shown to be the major PGD2-related receptors that have central roles in the regulation of the functions of several cells crucial in allergic diseases.66

Fevipiprant (QAW039) is an antagonist of PGD2 receptor CRTH2, which is expected to provide benefit in asthma by binding to CRTH2 receptors on eosinophils, basophils and T lymphocytes in the blood and tissues, thus inhibiting the migration and activation of these cells into the airway tissues and blocking the PGD2-driven release of Th2 cytokines.67 QAW039 is an interesting and unique molecule with ongoing Phase II and III RCTs that are recruiting patients with severe refractory allergic asthma Steps 4–5 Global Initiative for Asthma 2016. Fevipiprant, compared to all other mAbs, has the advantage of daily oral administration at dosages up to 500 mg. Preliminary data confirm a good safety profile and improvement of FEV1, especially in patients with more severe obstruction.68 Another Phase II study in patients with uncontrolled allergic asthma showed no improvement in pulmonary function. However, a subgroup analysis revealed that patients with impaired respiratory function (FEV1 <70%) had improved pulmonary function and asthma control when treated with QAW039.69 In a subsequent randomized, single-center, double-blind, parallel-group, placebo-controlled study on 61 patients with moderate-to-severe asthma, fevipiprant reduced eosinophilic airways and sputum inflammation and was well tolerated, confirming the good perspective of this drug for the near future.70

**Not only biologic therapies: BT**

BT is an endoscopic procedure approved by the FDA in 2010 for the treatment of severe refractory asthma. This method is essentially based on the delivery of 65° radiofrequency by a disposable catheter with 2.0 mm diameter introduced into the fibrobroncoscope operating channel (Alair®).70 BT is a one-time procedure that is completed after three treatments performed ~20 days apart, and several studies have demonstrated its long-term safety and effectiveness in terms of reducing serious exacerbations, improving health-related QoL, and reducing the number of working/school days lost for asthma.72–74 BT should always be used as an add-on treatment with the best standard care (Table 1). Due to its complex procedure, BT should always be performed in centers with adequate preparation and experience to handle possible intra- and postprocedure adverse events.75 Moreover, the significant increase in direct costs could represent another limiting factor. However, these costs are lower if compared with those associated with the use of biologic therapies for serious asthma (in particular, omalizumab), especially for long-term treatments, as demonstrated by several studies.76,77 There are still many open questions about the mechanism of action, selection of patients and their management. However, a reduction of airway smooth muscle and inflammation has been observed,78,79 also with regard to a possible reduction of blood eosinophils after BT.80 Some evidence reveals the possible effects of BT on the small airways, which is very important in asthma pathogenesis.81 It has also been argued that BT may influence the neuroendocrine epithelial cells, bronchial nerve endings, destruction of TRPV1 nerve receptors and the type-C unmyelinated fibers in the mucosa by interrupting central and local reflexes responsible for the activation of bronchospasm and bronchial hyperreactivity.82 All these aspects go beyond what was first hypothesized about the mechanisms of action, but they need further confirmation. However, several questions remain open regarding the phenotyping of patients and the long-term effects, but further improvements and clarifications will be expected in the next few years.

Based on the literature data and treatments available, BT may be already proposed for several patients: 1) patients with FEV1 ≥60% of the predicted,71 unsuitable for the currently available biodrugs (omalizumab or mepolizumab); 2) patients responsive to these mAbs and 3) patients who do not want to undergo biologic therapies with an indefinite duration (Figure 2). There are, however, studies on small patient groups such as Döing et al’s work on eight patients with severe functional impairment (FEV1 between 52% and 37% of the predicted), where BT was found to be effective in five of them without causing worsening of respiratory function.83 BT may also be indicated in patients with frequent exacerbations and hospitalization, regardless of T1 or T2 phenotype or respiratory function. Another potentially suitable subgroup could be composed of patients with severe steroid-resistant refractory asthma.85

**Growing role of biomarkers in asthma phenotyping and for the drug choice**

In clinical practice, asthma management and its follow-up are mainly based on respiratory function parameters that determine hyperreactivity and bronchial obstruction. However, these data do not always correlate with the levels and type of respiratory inflammation. Fibrobronchoscopy and bronchoalveolar lavage are the gold standard for defining inflammation, but are invasive and not routinely applicable.
Omalizumab has been helping the definition of asthma phenotypes and endotypes, thanks also to the identification of new and useful biomarkers to guide the choice of treatment. Therefore, for omalizumab, the selection of patients and the predictability of drug response are still based on the total free IgE level. In this regard, it is demonstrated that a high percentage of patients with severe bronchial obstruction often have total IgE values >400 IU/mL and that low IgE levels, on the other hand, usually have little therapeutic benefit with omalizumab. Although lower baseline levels of total IgE were potentially predictive of poor response to omalizumab as emerged from the INNOVATE study, subsequent pooled analysis did not clearly confirm this conclusion and showed treatment benefits regardless of the IgE levels.

As for other possible biomarkers, the level of blood eosinophilia is a parameter that effectively correlates with the response to anti-IL-5 mAbs, especially with >300 cells/μL or better than 500 cells/μL, while the FeNO reliability data are still partially controversial in determination and follow-up of eosinophilic inflammation. However, the EXTRA study showed that high values of blood eosinophilia and FeNO can positively predict the response to omalizumab, and patients with these phenotypic characteristics lose treatment benefits more quickly in case of its withdrawal, as demonstrated by the recent XPORT study.

All these aspects increase the difficulty in choosing from one of the two classes of biologics in case of overlapping, although several efficacy and safety data over the long-term use of omalizumab would favor this drug. Currently, no comparative direct data are available between anti-IgE and anti-IL5; so, considering a possible partial overlap between omalizumab- and mepolizumab-ineligible patients, head-to-head comparative trials will be needed to evaluate the efficacy of the two classes of mAbs. For this reason, switch studies from omalizumab to mepolizumab are currently on recruitment. The aim will be to compare these two drugs in terms of improving the QoL and reducing the frequency of clinically significant exacerbations, which may provide additional data to select the most suitable drug. From a recent meta-analysis study, it has been found that the observed heterogeneity and the different selection criteria for the use of the two drugs do not allow to formulate definitive recommendations for the preferential use of omalizumab versus mepolizumab, and no significant differences in effectiveness were detected.

However, it is important to remember that the atopic condition and the total IgE level at baseline do not affect the efficacy of mepolizumab, as demonstrated by a subanalysis of the DREAM trial. A recent post hoc analysis of patients treated with mepolizumab after an ineffective omalizumab treatment and enrolled in the DREAM, MENSA and SIRIUS studies showed that these patients positively responded to mepolizumab, regardless of the prior use of omalizumab. This result confirms and reinforces the conclusions of previous studies.

An extensive interventional cross-sectional study on a cohort of 670 patients was intended to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Preliminary data showed a 53% potential overlap between mepolizumab and omalizumab and a 16.8% overlap with reslizumab, confirming that common eligibility is often present between the two drug classes.

Promising biomarkers such as periostin will be able to help the clinician. Periostin is an extracellular matrix protein that is also associated with eosinophilic flogosis and is primarily studied to predict the response and monitor the biodrugs such as lebrikizumab and omalizumab. However, the correlation with eosinophilic inflammation was not always univocal; therefore, additional data are still needed. In addition, it has been shown that periostin is not just an indicator of type 2 inflammation activated by IL-13. Patients with asthma and high periostin levels have unique characteristics, including eosinophilia, high levels of nitric oxide, acetylsalicylic acid intolerance, nasal polypsis and late-onset asthma. These features are probably correlated with the involvement of periostin in bronchial remodeling, and this protein may also be associated with poor response to corticosteroids, probably due to tissue remodeling.

In addition, periostin has an accurate predictive power of response to mAbs such as lebrikizumab, tralokinumab and omalizumab, especially if combined with other parameters such as the level of blood eosinophilia and FeNO.

The increasing interest about the identification of biomarkers capable of predicting the effectiveness that guides the identification and choice of innovative therapies is represented by the Unbiased BIOmarkers for the Prediction of Respiratory Disease Outcomes project. This project is funded by the European Commission Innovative Medicines Initiative of the European Union, which has proposed a systematic algorithmic approach to patients with severe asthma.

Conclusion

The increase in therapeutic options for the treatment of asthma has made the subject of phenotyping and personalized therapy very timely. However, it is difficult to choose the right therapeutic target because of the complexity of pathogenesis,
severity and inflammatory pathways. After the introduction of omalizumab, BT and mepolizumab and the advent of other biologically active drugs, the multimodal approach of the management of patients with severe asthma becomes a key point. This is due to the possible overlap between anti-IgE and anti-IL-5 mAbs (as could be the case in patients with allergy and concomitant hypereosinophilic phenotype) and the difficulty in identification of patients eligible for BT.

The development and application of a broader scale of reproducible, noninvasive, cheap and validated biomarkers will make the treatment selection easier, but those already available, if properly used, can guide the clinician to the right therapeutic option for the right patient.

Pharmacoeconomic aspects must also be considered due to the high direct cost of new therapies. These costs are partially balanced by a better control of asthma; however, they should empower the clinician to the best positioning of current and future treatments. All these actions will avoid waste of valuable resources, especially in the actual socioeconomic context.

Disclosure
Francesco Menzella participated in contracted research and the clinical trials for Novartis, Sanofi and GlaxoSmithKline. Nicola Facciolongo served as a consultant for Boston Scientific. The other authors report no conflicts of interest in this work.

References


